Stockscreener 앱 받기
0.7364
2.05%
0.0148
시간 외 거래:
.74
0.0036
+0.49%
전일 마감가:
$0.7216
열려 있는:
$0.73
하루 거래량:
1.59M
Relative Volume:
0.67
시가총액:
$29.08M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-0.5486
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+11.26%
1개월 성능:
-82.99%
6개월 성능:
-66.68%
1년 성능:
-76.40%
1일 변동 폭
$0.715
$0.767
1주일 범위
$0.6351
$0.767
52주 변동 폭
$0.6311
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.7364 | 28.50M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
VistaGen’s PALISADE-3 trial fails primary endpoint in SAD - MSN
Aug Volume: Should I hold or sell Vistagen Therapeutics Inc stock in 2025July 2025 Intraday Action & Stepwise Trade Execution Plans - moha.gov.vn
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short Interest - Defense World
Vistagen Therapeutics Inc (VTGN) deserves deeper analysis - uspostnews.com
ATTENTION VTGN SHAREHOLDERS: Investors who Lost Money on Vistagen Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Lost Money on Vistagen Therapeutics, Inc.(VTGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Vistagen Therapeutics (VTGN) price target decreased by 50.00% to 7.40 - MSN
VTGN STOCK ALERT: Levi & Korsinsky Notifies Vistagen Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
William Blair downgrades Vistagen Therapeutics (VTGN) - MSN
Finance Watch: Vistagen To Cut Costs After Phase III Trial Failure - Citeline News & Insights
Levi & Korsinsky Announces an Investigation on Behalf of Vistagen Therapeutics, Inc. (VTGN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint - Investing.com Australia
Vistagen Therapeutics reports Phase 3 trial for fasedienol did not meet endpoint By Investing.com - Investing.com South Africa
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD - TipRanks
Vistagen Therapeutics Reports Phase 3 Study Results - TradingView — Track All Markets
Vistagen Therapeutics, Inc. (VTGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
How Vistagen Therapeutics Inc. stock reacts to bond yieldsWeekly Trade Analysis & Daily Growth Stock Investment Tips - Улправда
Can Vistagen Therapeutics Inc. stock sustain institutional interestJuly 2025 Selloffs & Reliable Momentum Entry Alerts - Улправда
Update Recap: Why retail investors pile into Vistagen Therapeutics Inc. stockPortfolio Performance Report & Accurate Entry and Exit Point Alerts - Улправда
Can Vistagen Therapeutics Inc. stock deliver consistent earnings growth2025 Sector Review & Momentum Based Trading Signals - Улправда
Can Vistagen Therapeutics Inc. stock beat analyst upgrades2025 Price Momentum & Precise Entry and Exit Recommendations - DonanımHaber
Why retail investors pile into Vistagen Therapeutics Inc. stockJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
Aug Selloffs: What Wall Street predicts for Vistagen Therapeutics Inc. stock priceQuarterly Portfolio Review & Daily Growth Stock Tips - Улправда
VTGN ACTIVE INVESTIGATION: Lost Money on Vistagen Therapeutics, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Shareholders Alert: Investigation Into Vistagen Therapeutics, Inc. (VTGN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Vistagen tanks after fasedienol Phase III miss - The Pharma Letter
Jefferies Downgrades Vistagen Therapeutics to Hold From Buy, Adjusts Price Target to $0.90 From $15 - marketscreener.com
Vistagen appoints Nick Tressler as CFO - MSN
Vistagen Therapeutics (VTGN) Receives Downgrade from William Bla - GuruFocus
Vistagen downgraded to market perform from outperform at William Blair - MSN
VistaGen Therapeutics trading resumes - MSN
Downgrade Alert: Vistagen Therapeutics (VTGN) Target Price Slashed | VTGN Stock News - GuruFocus
Vistagen stock craters after social anxiety study comes up empty - FirstWord Pharma
Vistagen Therapeutics (VTGN) Downgraded by Maxim Group | VTGN St - GuruFocus
Vistagen (VTGN) Stock: Plunges 79% After Disappointing Phase 3 Trial Results - parameter.io
Jefferies downgrades VistaGen stock rating to Hold on failed Phase III trial - Investing.com
VistaGen stock rating downgraded by William Blair after trial miss - Investing.com Canada
Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst - Fierce Biotech
Vistagen’s anxiety treatment fails to meet primary endpoint in trial By Investing.com - Investing.com Nigeria
Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study - Psychiatric Times
Maxim Downgrades Vistagen Therapeutics to Hold From Buy - marketscreener.com
William Blair Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Stifel downgrades VistaGen stock to Hold as anxiety drug fails in trial - Investing.com Canada
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints - TipRanks
Why Did Vistagen Stock Tank 82% Today? - Stocktwits
Vistagen (VTGN) Faces Setback as Phase 3 Trial Misses Primary En - GuruFocus
Vistagen downgraded to Neutral from Buy at Lucid Capital - TipRanks
Vistagen (VTGN) Phase 3 Study Results for Social Anxiety Treatme - GuruFocus
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):